Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × Breast Neoplasms × X-Rays × Clear all

Phase

Status

Completed 3 Terminated 2 Not yet recruiting 2 Active not recruiting 2 Withdrawn 1 Unknown 1 Recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Mouth Neoplasms 2 Laryngeal Neoplasms 2 Hypopharyngeal Neoplasms 2 Carcinoma 2 Triple Negative Breast Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Prostatic Neoplasms 1 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1 Oropharyngeal Neoplasms 1 Lymphoma, Mantle-Cell 1 Lymphoma, B-Cell 1 Hematologic Neoplasms 1 Colorectal Neoplasms 1 Burkitt Lymphoma 1 Breast Neoplasms 1 Barrett Esophagus 1 Advanced Cancers 1

Interventions

Paclitaxel 20 Trastuzumab 17 Docetaxel 13 Cyclophosphamide 13 Capecitabine 10 Letrozole 9 Doxorubicin 9 exemestane 8 Radiotherapy 8 Fulvestrant 8 Lapatinib 7 Carboplatin 7 pembrolizumab 6 Goserelin 6 Anastrozole 6 palbociclib 5 eribulin 5 Therapeutics 5 Neoadjuvant Therapy 5 Chemotherapy, Adjuvant 5 Bevacizumab 5 Aromatase Inhibitors 5 tucatinib 4 abemaciclib 4 Vinorelbine 4 Taxes 4 Mastectomy, Segmental 4 Magnetic Resonance Spectroscopy 4 Exercise 4 Epirubicin 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01714128 2021-10-25

FES-PET for Patients Treated on NCI Protocol 8762

Washington University School of Medicine

Phase NA Withdrawn

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡